IPW



#### PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8359

Wayne Charles WIDDISON

Appln. No.: 10/633,616

Group Art Unit: 1654

Confirmation No.: 5387

Examiner: Edward C. Ward

Filed: August 16, 2002

For:

CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE

IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL

MOLECULE DRUGS

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith, along with a copy of the International Search Report issued in the corresponding PCT application.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes

A8359

INFORMATION DISCLOSTRE STATEMENT

U.S. Appln. No.: 10/633,616

A . 16 74

prosecution in the application (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The present Information Disclosure Statement is being filed thirty days or fewer from the communication from a foreign patent office and a Statement Under 37 C.F.R. §1.704(d) is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373 CUSTOMER NUMBER

Date: May 25, 2004

### PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of

Docket No: A8359

Wayne Charles WIDDISON

Appln. No.: 10/633,616

Group Art Unit: 1654

Confirmation No.: 5387

Examiner: Edward C. Ward

Filed: August 16, 2002

CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE For:

IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL

MOLECULE DRUGS

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

Registration No. 30,951

Susan J. Maćk

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

> WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: May 25, 2004

	4.				
	Substitute for Form 1449 A & B/PTO	Complete if Known			
		Application Number	10/633,616		
6	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Confirmation Number	5387		
_	STATEMENT BY APPLICANT	Filing Date	August 16, 2002		
. •	\	First Named Inventor	Wayne Charles WIDDISON		
M	(use as many sheets as necessary)	Art Unit	1654		
	[ \ \varepsilon \varepsilon \rangle \]	Examiner Name	Edward C. Ward		
Er	Practice 1 of 1	Attorney Docket Number	A8359		
-	S TRADES		·		

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number		Publication Date			
Initials*	No.1	Number	Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US 6,441,163	B1	08-27-2002	Chari, et al.		
		US 4,563,304		01-07-1986	Carlsson, et al.		
	-						
		•					
			_				
	**		<u> </u>				
		· · · · · · · · · · · · · · · · · · ·					
		<u> </u>	<u> </u>		<u> </u>		

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document		Publication Date	Name of Patentee or		
Initials*	No.1	Country Code <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
	-						
	-						

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>		
		YOKOYAMA et al. "Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol-block-(aspartic acid) as intermediate carrier." Makromol. Chem. 1989, Vol. 190 pages 2041-2054, see page 2047, and page 2050			

			_
		1	
	10.0.1		
Examiner Signature	Date Considered		
Distinct Distincture	25 411 0 0 1 1 1 1 1		_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.